Biotech

Companies & Industries News

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Biotech

Top news of the week: 07.09.2022.

Form 10-K
Form 10-Q
Proteins
Allergy
Health care
Classified information

@biospace shared
On Sep 2, 2022
The problem of intellectual property theft is greater than most biopharma executives realize, but the real issue is that companies are protecting only a fraction of their IP. https://t.co/PMinB2KfQu
Open
Biopharma Needs Protect more than Crown Jewel IP Stay Competitive

Biopharma Needs Protect more than Crown Jewel IP Stay Competitive

The problem of intellectual property theft is greater than most biopharma executives realize, but the real issue is that companies are protecting only a fraction of their IP.

@biospace shared
On Sep 2, 2022
@immusoft is heading into the clinic with what it claims is the first engineered B cell gene therapy cleared for in-human study, the company announced Thursday. https://t.co/2Uh4PzslhS
Open
Immusoft Takes First-Ever Engineered B Cell Therapy into Clinic

Immusoft Takes First-Ever Engineered B Cell Therapy into Clinic

Immusoft is heading into the clinic with what it claims is the first engineered B cell gene therapy cleared for in-human study, the company announced Thursday.

@BiotechWorld shared
On Sep 2, 2022
Bio-Techne to Seek Approval to Implement Four-for-One Stock Split - Sep 01, 2022 https://t.co/01CA494r5q
Open
Bio-Techne to Seek Approval to Implement Four-for-One Stock Split - Sep 01, 2022

Bio-Techne to Seek Approval to Implement Four-for-One Stock Split - Sep 01, 2022

Bio-Techne to Seek Approval to Implement Four-for-One Stock Split - Sep 01, 2022 - read this article along with other careers information, tips and advice on BioSpace

@BiotechWorld shared
On Sep 1, 2022
Arch Therapeutics Submits Application to Centers for Medicare and Medicaid Services for AC5® Advanced Wound System https://t.co/MTBpU85IH8
Open
Arch Therapeutics Submits Application to Centers for Medicare and Medicaid Services for AC5® Advanced Wound System

Arch Therapeutics Submits Application to Centers for Medicare and Medicaid Services for AC5® Advanced Wound System

Arch Therapeutics Submits Application to Centers for Medicare and Medicaid Services for AC5® Advanced Wound System - read this article along with other careers information, tips and advice ...

@KBIBiopharma shared
On Sep 2, 2022
We recently spoke with our DSPD team about their recently-published paper providing a verified protocol for rapidly determining DBC for various molecules (including mAbs and fusion proteins). Read the Q&A here: https://t.co/37lhnK7zST
Open
Faster Determination of Dynamic Binding Capacity – Q&A With KBI’s Scientific Team

Faster Determination of Dynamic Binding Capacity – Q&A With KBI’s Scientific Team

This work provides a verified protocol and comprehensive analysis for determining DBC for various molecules based on inline variable pathlength tech.

@sanofi shared
On Sep 5, 2022
With @Regeneron, we’re presenting late-breaking, two-year data in children aged 6 to 11 years with uncontrolled asthma at #ERSCongress. Learn more about these Phase 3 data results: https://t.co/DYEmj1xofq https://t.co/p8an31cg1m
Open
Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma

Press Release: Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma

Late-breaking Dupixent® (dupilumab) data at ERS 2022 show consistent efficacy and safety profile for up to two years in children aged 6 to 11 years with moderate-to-severe asthma …

@biospace shared
On Sep 2, 2022
As the monkeypox outbreak continues in the United States and other parts of the world, researchers and public health officials scramble to test known drugs against the disease. https://t.co/2Mvlm9ppgV
Open
Research Roundup: TPOXX Found Effective Against Monkeypox and More

Research Roundup: TPOXX Found Effective Against Monkeypox and More

As the monkeypox outbreak continues in the U.S. and abroad, researchers and health officials race to test drugs against the disease. For that and more research stories, continue reading.

@BiotechWorld shared
On Sep 5, 2022
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Sep 02, 2022 https://t.co/agCOdgz3My
Open
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Sep 02, 2022

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Sep 02, 2022

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) - Sep 02, 2022 - read this article along with other careers information, tips and advice on BioSpace

Read more:
weekly 07.09.2022
View archives
Back to home

Subscribe to Biotech - Companies & Industries.

Avoid an information overload and get the most trusted industry news hand-picked by the top Experts. Sign up for the weekly Biotech - Companies & Industries.
Privacy Policy

Sign up for the weekly Biotech - Companies & Industries newsletter

Never again miss anything or anyone that matter in Biotech

Sign up and receive the Biotech - Companies & Industries weekly email newsletter directly to your inbox. Make more informed business decisions based on insight for the most trusted industry experts, faster.
Privacy Policy